Introduction of the anti-CD20 monoclonal antibody rituximab in 1997 substantially improved prognosis after a diagnosis of diffuse large B-cell lymphoma (DLBCL),¹ which affects > 27,000 individuals in the United States annually.² With the 5-year relative survival increasing from 43% in the early 1990s to > 65% since 2010 (Fig 1),³ attention has increasingly turned toward improving understanding of patients’ long-term health after DLBCL.

中文翻译：

---

对弥漫性大型B细胞淋巴瘤幸存者的长期免疫健康的新颖见解。

在诊断为弥漫性大B细胞淋巴瘤（DLBCL）¹之后，1997年抗CD20单克隆抗体利妥昔单抗的引入大大改善了预后，在美国每年影响27,000多人。²随着5年相对生存率从1990年代初的43％增加到2010年以来的> 65％（图1），³的注意力日益朝着改善患者的DLBCL经过长期的健康的认识转身。